Initial payment of 250 million dlr, then up to 1.27 billion – Rome, 03 Oct – The British pharmaceutical company AstraZeneca has reached an agreement with the manufacturer of the anti-wrinkle treatment Allergan, for the license of a drug against intestinal diseases. Under the terms of the agreement, Allergan will initially pay $250 million for the rights to develop and commercialize Medi20700, a drug for the treatment of inflammatory bowel diseases such as Crohn's disease. In a second step, the US group could pay up to 1.27 billion dollars, a sum that will depend on the success in the development and sale of the drug.
(RADIOCOR) 03-10-16 09:38:24 (0175)SAN 5 NNNN
Source Borsa Italiana – (Il Sole 24 Ore Radiocor Plus)
Related news: AstraZeneca licenses inflammatory disease candidate to Allergan
Facebook Founder's Science Group Hires AstraZeneca Board Member
